嗜中性白血球低下症治療的全球市場 - 2022年～2029年

本報告提供全球嗜中性白血球低下症治療市場相關調查，提供市場概要，以及不同治療，各劑型，各終端用戶，各地區趨勢，競爭情形，及加入此市場的主要企業簡介等資訊。

目錄

第1章 全球嗜中性白血球低下症治療市場調查手法和範圍

第2章 全球嗜中性白血球低下症治療市場-市場定義和概要

第3章 全球嗜中性白血球低下症治療市場-摘要整理

• 不同治療，市場明細
• 各劑型，市場明細
• 各終端用戶，市場明細
• 各地區，市場明細

第4章 全球嗜中性白血球低下症治療市場-市場動態

• 影響市場的要素
  • 促進因素
  • 阻礙因素
  • 市場機會
  • 影響分析

第5章 全球嗜中性白血球低下症治療市場-產業分析

• 波特的五力分析
• 供應鏈分析
• 法規分析

第6章 全球嗜中性白血球低下症治療市場-COVID-19分析

第7章 全球嗜中性白血球低下症治療市場-不同治療

• 簡介
  • 市場規模分析，及與前一年同期比較成長分析(%)、不同治療
  • 市場魅力指數，不同治療
• 抗生素
  • 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
• 顆粒細胞增生因子
• 抗真菌劑
• 其他

第8章 全球嗜中性白血球低下症治療市場-各劑型

• 簡介
  • 市場規模分析，及與前一年同期比較成長分析(%)、各劑型
  • 市場魅力指數，各劑型
• 膠囊
  • 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
• 注射

第9章 全球嗜中性白血球低下症治療市場-各終端用戶

• 簡介
  • 市場規模分析，及與前一年同期比較成長分析(%)、各終端用戶
  • 市場魅力指數，各終端用戶
• 院內藥局
  • 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
• 零售藥局
• 線上藥局
• 其他

第10章 全球嗜中性白血球低下症治療市場-各地區

• 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)，各地區
  • 市場魅力指數，各地區
• 北美
• 歐洲
• 南美
• 亞太地區
• 中東·非洲

第11章 全球嗜中性白血球低下症治療市場-競爭情形

• 主要的發展與策略
• 企業佔有率分析
• 產品的基準

第12章 全球嗜中性白血球低下症治療市場-企業簡介

• Kyowa Kirin Co Ltd
• Amgen Inc
• Novartis AG
• Pfizer Inc
• Dr.Reddy Laboratories
• Intas Pharmaceuticals

第13章 全球嗜中性白血球低下症治療市場-DataM

Market Overview

The global neutropenia treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Neutropenia is a disorder in which the number of circulating neutrophils, a type of white blood cell found in the blood, is abnormally low. The bulk of circulating lymphocytes is these cells, which help protect the body from infections caused by bacteria, viruses, and other harmful organisms. A drop in neutrophil levels in the blood makes a patient more susceptible to infection and fatal. As a result, prevention is required right away.

Market Dynamics

The global neutropenia treatment market growth is driven by is the development of new treatments in conjunction with an increase in cases of chemotherapy-induced neutropenia. Furthermore, the novel drug delivery strategy increases patient convenience, resulting in greater adherence to the patient and, as a result, stimulating market growth.

The Increasing in research and development and development of new drugs will drive the market growth

The neutropenia treatment industry is expected to grow significantly due to major industry players supporting research and development as well as public awareness of neutropenia therapy. As major market tactics, companies in this market are focusing on increasing knowledge about preventive measures, early diagnosis, and effective treatment of neutropenia. The introduction of small molecules is one of the new developments gaining traction in the global neutropenia treatment market. BeyondSpring Pharmaceuticals' development of Plinabulin, a small molecule with immune-boosting properties, is expected to revolutionize neutropenia treatment. In addition to immune-boosting effects, Phase II studies have revealed that this molecule has far more beneficial anti-cancer effects. There is currently a high demand for cost-effective drugs in the neutropenia treatment market. As a result, vendors concentrate on producing small molecules with lower processing costs than biologics. Amgen introduced the Neulasta (Pegfilgrastim) Delivery Kit in April 2017. This kit is a novel drug delivery method that allows for the self-administration of Neulasta, which aids in the stimulation of white blood cell production.

Moreover, chemotherapy is commonly used to target neoplastic cells. However, while this therapy is effective against most cancers, the cells of the hematopoietic system, which produces billions of blood cells needed daily, are highly sensitive to it, resulting in blood cell population loss. Chemotherapy-induced neutropenia is the medical term for this condition. In chemotherapy-induced neutropenia, the body has a low level of neutrophils, which are types of white blood cells. According to the Lancet Oncology journal, chemotherapy was used by 58 percent of new cancer patients (9.8 million out of 17 million) worldwide in 2018. According to the report, the number of new cancer cases will rise to 26 million by 2040, with chemotherapy accounting for 53 percent (15 million out of 26 million) of the total (an estimated 5.2 million new cancer cases). Eastern Asia would house more than one-third of the 15 million people who would require chemotherapy in 2040. (5.2 million, 35 percent ).These factors will drive the growth of neutropenia treatment market.

The patent expiration of the most preferred drugs is likely to hamper the market growth

Chemotherapy is the most commonly used cancer treatment. The rising use of chemotherapy will propel the chemotherapy-induced neutropenia treatment market forward. However, market revenue is expected to decrease due to the patent expiration of the most preferred drugs to treat chemotherapy-induced neutropenia and the emergence of various biosimilars. However, as biosimilars become more common, this condition will be balanced.

COVID-19 Impact Analysis

The neutropenia treatment market shrank significantly during the COVID-19 pandemic. The pandemic has made it more difficult to bring new medications to market in the hopes of gaining market share or exceeding sales targets. Aside from new diagnoses and regimen changes, marketing channels aren't as robust as before the epidemic. COVID-19 programming continues to dominate the few available channels. COVID-19 has slowed clinical trials in general, particularly those in the early stages of development. With the closure of traditional study sites, researchers frequently could not collect data remotely, and many patients became less willing to participate. Some therapeutic fields were especially badly damaged. While some development time can be made up, there are concerns about resource allocation and digital technology expenditures to keep trials running in the present and future.

Segment Analysis

The granulocyte colony stimulating factor segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The Granulocyte-colony stimulating factor (G-CSF) drug class dominated the overall neutropenia treatment market in 2018 as the first-line of action and the only target-specific drug approved by regulatory bodies. G-CSF stimulates the production of granulocytes in neutropenic patients, increasing the number of white blood cells. G-CSF is prescribed to cancer patients as primary prophylaxis, which refers to its use after the first cycle of chemotherapy but before the development of neutropenia to prevent further complications. SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon (Shanghai) Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.), and Plinabulin (BeyondSpring Pharmaceuticals Inc.) are among the products in phase III clinical trials for neutropenia treatment.

According to a 2019 Cancer.net study, approximately 50% of cancer patients undergoing chemotherapy have some level of neutropenia. According to the American Cancer Society (ACS), there were 1.7 million new cancer cases and 0.6 million cancer deaths in the United States in 2019. As a result, the rise in cancer incidence rates worldwide is expected to drive demand for the neutropenia biologic drug treatment market in the coming years.These factors are driving the growth of this segment.

Geographical Analysis

North America region holds the largest market share of the global neutropenia treatment market

North America is anticipated to dominate the neutropenia treatment market, globally. The factors attributed to the high growth of the region are due to increase in the prevalence of various types of cancer, an increase in government research funding, and an increase in cases of chemotherapy-induced side effects among cancer survivors. According to World Health Organization, cancer is the leading cause of death globally, accounting for nearly 10 million deaths in 2020, or nearly one in every six deaths. The most common cancers are breast, lung, colon, rectal, and prostate cancer. Tobacco use, a high BMI, alcohol consumption, a lack of fruits and vegetables, and physical activity account for roughly one-third of cancer deaths. Infections that cause cancer, such as human papillomavirus (HPV) and hepatitis, account for approximately 30% of cancer cases in low- and lower-middle-income countries.

Furthermore, organic and inorganic strategies such as mergers and acquisitions and partnerships among key market players will strengthen their product portfolios in the studied market, driving the market. In addition, several product launches in the market will lead to profitable market growth. For instance, in Februray 2018, Partner Therapeutics, a Boston-based cancer company, paid $60 million for Sanofi's Leukine (Sargramostim). Leukine is the only FDA-approved recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of acute myelogenous leukemia (AML) in older adults, and it is used in both allogeneic and autologous bone marrow transplantation. Furthermore, advancements in various neutropenia treatment from established key players, in the United States, are likely to drive the market growth in North America.

Competitive Landscape

The neutropenia treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc, Novartis AG, Pfizer Inc, Kyowa Kirin Co Ltd(Kirin Company), Dr.Reddy, Intas Pharmaceuticals among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the neutropenia treatment market globally. For instance, In August 2020, Asalyxa Bio declared its formation and seed funding to move ASX-100 into human trials in 2021. ASX-100 is a novel spherical particle that directly delivers a safe and effective anti-inflammatory agent, salicylic acid, to overactive immune cells and treats severe neutrophil-mediated disease.

Kyowa Kirin Co Ltd

Overview:

Kyowa Kirin is a life science R&D company with a focus on biotechnology. The Kyowa Kirin Group companies strive to improve people's health and well-being worldwide by creating new value through advances in life sciences and technology.

Product Portfolio:

GRAN: GRAN® (Filgrastim) is a human colony-stimulating factor (G-CSF) created through genetic recombination. It works by selectively increasing the number of a type of white blood cell known as neutrophils and their functional efficacy. This allows for a faster recovery from neutropenia caused by cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy. It also works to treat congenital and neutropenia caused by hematopoietic stem-cell transplantation (such as bone-marrow transplants). It received approval for PBSCT (peripheral blood stem cell transfusion) mobilization.

Why Purchase the Report?

Visualize the composition of the global neutropenia treatment market segmentation by treatment, dosage form, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global neutropenia treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global neutropenia treatment market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global neutropenia treatment market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Global Neutropenia Treatment Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Neutropenia Treatment Market-Market Definition and Overview

3. Global Neutropenia Treatment Market- Executive Summary

• 3.1. Market Snippet By Treatment
• 3.2. Market snippet By Dosage Form
• 3.3. Market Snippet By End User
• 3.4. Market Snippet by Region

4. Global Neutropenia Treatment Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing in prevalence of leukemia
    • 4.1.1.2. Surge in research and development
    • 4.1.1.3. Shifting from branded drugs to biosimilars in cancer supportive treatment
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of the treatment of neutropenia
    • 4.1.2.2. Strict rules and regulation for product approvals
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Neutropenia Treatment Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. Global Neutropenia Treatment Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Neutropenia Treatment Market- By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Segment
  • 7.1.2. Market Attractiveness Index, By Treatment Segment
• 7.2. Antibiotics*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Granulocyte colony stimulating factor
• 7.4. Antifungual Drugs
• 7.5. Others

8. Global Neutropenia Treatment Market- By Dosage Form

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
  • 8.1.2. Market Attractiveness Index, By Dosage Form
• 8.2. Capsule*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Injection

9. Global Neutropenia Treatment Market- By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User Segment
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies
• 9.5. Others

10. Global Neutropenia Treatment Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Neutropenia Treatment Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Global Neutropenia Treatment Market- Company Profiles

• 12.1. Kyowa Kirin Co Ltd*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Amgen Inc
• 12.3. Novartis AG
• 12.4. Pfizer Inc
• 12.5. Dr.Reddy Laboratories
• 12.6. Intas Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Global Neutropenia Treatment Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us